ProShares Ultra NASDAQ Biotechnology (BIB) seeks to deliver twice (2x) the daily performance of the NASDAQ Biotechnology Index, which measures the performance of biotechnology and pharmaceutical companies listed on NASDAQ. This leveraged ETF provides amplified exposure to companies developing drugs, medical devices, and biotechnology innovations.
How It Works
BIB uses derivatives including swaps and futures contracts to achieve 200% daily exposure to its underlying index. The fund rebalances daily to maintain its 2x leverage target, meaning it seeks to double the index's daily moves—not longer-term returns. Holdings are concentrated in approximately 200-300 biotech stocks, with larger companies like Moderna, Gilead Sciences, and Amgen receiving proportionally higher allocations based on market capitalization weighting.
Key Features
- Provides 2x leveraged exposure to biotech sector, amplifying both gains and losses compared to unleveraged biotech ETFs
- Daily rebalancing maintains precise leverage but creates compounding effects that deviate from 2x long-term index returns
- Focuses exclusively on NASDAQ-listed biotechnology companies, excluding broader pharmaceutical giants from other exchanges
Risks
- Daily reset causes compounding decay—if biotech index drops 10% then rises 10%, BIB does not return to break-even due to leverage mathematics
- This ETF can lose 40-60% in a single day if biotech sector crashes 20-30%, with potential for near-total loss during extended downturns
- Biotech stocks are highly volatile and speculative, often declining 50-70% when drug trials fail or regulatory approvals are denied
Who Should Own This
Designed for active traders with very high risk tolerance and holding periods of hours to days, not weeks or months. Requires constant monitoring and should represent no more than 1-5% of total portfolio. Suitable for tactical bets on short-term biotech momentum or hedging strategies, not long-term biotech exposure.